Skip to main content
STAR COMBO PHARMA LIMITED logo

STAR COMBO PHARMA LIMITED — Investor Relations & Filings

Ticker · S66 ISIN · AU0000004798 ASX Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2021-10-10 Capital/Financing Update
Country AU Australia
Listing ASX S66

About STAR COMBO PHARMA LIMITED

https://www.starcombo.com.au

Star Combo Pharma Limited specializes in the development, manufacturing, and distribution of vitamins, dietary supplements, and skincare products. The organization operates Therapeutic Goods Administration (TGA) licensed facilities, offering comprehensive Original Equipment Manufacturing (OEM) and Original Design Manufacturing (ODM) services. Its product portfolio encompasses a wide range of health and beauty solutions marketed under proprietary brands, including Costar, Living Healthy, Amax, and J&K. The company focuses on delivering premium health products to diverse markets, leveraging technical expertise in formulation and large-scale production. By maintaining rigorous quality control standards and providing end-to-end manufacturing solutions, the entity serves as a strategic partner for businesses seeking customized health and wellness products.

Recent filings

Filing Released Lang Actions
Vietnam Distributor Agreement Signed 2 pages 182.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 11 October 2021 from Star Combo Pharma Ltd. It details a new distribution agreement with a Vietnamese distributor for the company's health supplement products. The content focuses on the business development and strategic partnership to expand sales in the APAC region. There are no financial statements, regulatory certifications, voting results, or management changes discussed. The document is relatively short (4515 characters) and serves as a business update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. The best fitting category is Capital/Financing Update (CAP) because it announces a significant commercial agreement that could impact the company's capital or sales growth prospects, which is typical for CAP filings. Confidence is high given the clear nature of the announcement and its business development focus.
2021-10-10 English
Woodpark Road Smithfield - Site Expansion Update 2 pages 235.1KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 6 September 2021 from Star Combo Pharma Ltd. It provides an update on the approval of a Development Application for new R&D facilities and the recommencement of construction at an existing manufacturing site. The content focuses on operational updates and expansion plans rather than financial results, regulatory filings, or detailed financial statements. The document is relatively short (4171 characters) and serves as a corporate update rather than a formal report or filing. There is no indication of financial data, voting results, management changes, or legal proceedings. Therefore, the document best fits the category of a Capital/Financing Update (CAP) as it relates to company expansion and capacity increase, which are capital-related developments.
2021-09-05 English
Preliminary Final Report 64 pages 1.9MB
Annual Report Classification · 100% confidence The document is titled 'APPENDIX 4E PRELIMINARY FINAL REPORT FOR THE YEAR ENDED 30 JUNE 2021' and includes detailed financial data for the full fiscal year ended 30 June 2021. It contains a Directors' Report, Remuneration Report, Auditor's Independence Declaration, Financial Statements, Directors' Declaration, and Independent Auditor's Report. The presence of comprehensive financial statements and detailed management discussion indicates this is a full annual financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. The content matches the characteristics of an Annual Report (10-K equivalent) filing, which covers the full financial performance and company activity for the year. Therefore, the correct classification is Annual Report (10-K).
2021-08-24 English
S66 2021 Results Announcement 2 pages 169.6KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 24 August 2021, presenting financial highlights and operational updates for the year ended 30 June 2021. It includes detailed financial data such as operating cash flow, gross profit, revenue, impairment losses, and cash position. The document also discusses business developments, investments, contracts, and outlook for the next fiscal year. The length is 6753 characters, which is sufficient to contain substantive financial data and analysis. The content is a comprehensive financial update for a full fiscal year, indicating it is a full annual financial report rather than a brief earnings release or a report publication announcement. Therefore, the document fits the definition of an Annual Report (10-K) or equivalent annual financial report. Given it is an ASX announcement, it is likely a full annual report or a detailed financial results announcement for the fiscal year. The best fitting category is Annual Report (10-K).
2021-08-24 English
Quarterly Business Update 2 pages 151.7KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 28 April 2021 titled 'Star Combo Pharma Quarterly Business Update'. It provides a summary of business activities, operational updates, cash receipts, and outlook for the quarter ended 31 March 2021 (Q3 FY21). The content includes financial figures such as revenue and cash receipts, but it is a high-level business update rather than a comprehensive financial report with detailed financial statements or analysis. The document is about 5724 characters long, which is relatively short and consistent with an announcement rather than a full interim or quarterly report. It does not contain detailed financial statements or substantive financial data typical of an Interim/Quarterly Report (IR). Instead, it is a business update announcement to the market. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it provides updates on business operations and financial performance for the quarter without being a full financial report.
2021-04-27 English
S66 1H21 Result Announcement 22 pages 2.5MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 24 February 2021, titled "Star Combo Pharma Ltd 1H21 Result." It provides detailed financial results for the first half of the 2021 financial year, including NPAT, revenue, cash flow, segment performance, and operational highlights. The document contains substantive financial data, analysis, and outlook commentary for the half-year period. It is not merely an announcement of a report or a certification letter. The content aligns with a comprehensive interim or quarterly financial report rather than a brief earnings release or investor presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2021-02-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.